CBI’s 3rd Annual Forum on Industry Collaboration with Cooperative Groups

Attend the Only Forum that Unites Cooperative Groups and Industry!

Plans to consolidate the Cooperative Group System from nine to four groups are well underway.  This March, the forum features perspective from newly-consolidated groups as well as a global focus with presentations from the Korean Cancer Study Group (KCSG) and ECOG.  Bio/pharmaceutical and Cooperative Group attendees gain take-home strategies to help manage challenges in drug distribution, contracting and budgeting for this unique type of collaborative study.  With new timelines in place for trial activation, it is more important than ever for Cooperative Groups and industry to understand each others’ challenges and streamline coordinated efforts from initial LOI through study start-up.   

Your Questions Answered:

• What is the status of Cooperative Group Consolidation and what are the implications for industry collaborations?
  
  • NCI CTEP, The Alliance and NRG Oncology provide their perspectives
    
• How are Cooperative Groups facilitating global trials?
  
  • The Korean Cancer Study Group (KCSG) and ECOG provide perspective on globalization
    
• How do bio/pharmaceutical companies budget and contract for these types of studies?
  
  • Hear presentations and panels with perspective from Human Genome Sciences, SWOG, Genentech Oncology, BMS and The Alliance
    
• What mechanisms are available to distribute drug in these trials?
  
  • Ask panelists from NCI’s Pharmaceutical Management Branch, Pfizer Inc and SWOG your questions on drug distribution for multi-site and global trials
    

Attendee Profile: